Antipathogenic activity – MicrobiomePost

Lactobacillus gasseri LMG P-30998

Marco Marino — Wed, 16 Jul 2025 10:47:47 +0000

Strain isolated from feces from babies
Strain safe for human use: genome sequence (WGS) and safety data (antibiotic sensitivity) are available
Strain subjected to EU patent application and PCT
Strain stability in liofilized powder form available over 6 months

The strain was tested in vitro for the following features

the strain is sensitive to 9 antibiotics according to EFSA standards
the strain adheres to the Caco-2 epithelial intestinal cells
the strain is able to ferment prebiotics (FOS, IMO and lactulose)
the strain has antipathogenic activity, adhesive ability to intestinal cells, it survives the gastric and intestinal transit
the strain is able to activate the immune system to prevent possible viral infection: in its viable forms it induces IL-12p70 secretion in PBMCs

Lacticaseibacillus rhamnosus LMG P-31000

GiovanniAdmin — Wed, 16 Jul 2025 10:46:00 +0000

Strain isolated from feces from babies
Strain safe for human use: genome sequence (WGS) and safety data (antibiotic sensitivity) are available
Strain subjected to EU patent application and PCT
Strain stability in liofilized powder form available over 6 months

The strain was tested in vitro for the following features

the strain is sensitive to 9 antibiotics according to EFSA standards
the strain adheres to the Caco-2 epithelial intestinal cells
the strain is able to ferment prebiotics (GOS)
the strain has antipathogenic activity, adhesive ability to intestinal cells, it survives the gastric and intestinal transit
the strain has anti-microbial activity against pathogens in different human cell models (intestinal, vaginal, lung)

Bifidobacterium breve LMG P-30999

Marco Marino — Tue, 15 Jul 2025 11:57:58 +0000

Strain isolated from feces from babies
Strain safe for human use: genome sequence (WGS) and safety data (antibiotic sensitivity) are available
Strain subjected to EU patent application and PCT
Strain stability in liofilized powder form available over 6 months

The strain was tested in vitro for the following features

the strain is sensitive to 9 antibiotics according to EFSA standards
the strain adheres to the Caco-2 epithelial intestinal cells
the strain is able to ferment prebiotics (FOS, raffinose and lactulose)
the strain has antipathogenic activity and adhesive ability to intestinal cells, it survives the gastric and intestinal transit
the strain has immunomodulatory properties: it activates dendritic cells, stimulates CD86 and CD40 markers, promotes expression of MHC I and II that support mucolase and systemic immunity
the stain is able to to induce a two-fold induction in GLP-1 secretion in human L-cells (antidiabetogenic potential)

SynbÆctive® SmilinGut

GiovanniAdmin — Fri, 08 Sep 2023 11:06:21 +0000

SmilinGut is a probiotic complex by SynBalance, specifically designed to support gastrointestinal health. A randomized, double-blind, placebo-controlled trial in IBS-C subjects demonstrated significant symptom improvement within just 10 days. The results confirmed that the probiotic strains effectively colonized the gut, helping to restore microbial balance, inhibit the growth of gastrointestinal pathogens, and alleviate IBS-C symptoms.

SynbÆctive® Gumtastic

GiovanniAdmin — Fri, 08 Sep 2023 11:05:32 +0000

Gumtastic is a probiotic complex designed by SynBalance to target gum health. In-vitro testing highlighted the ability of the ingredient’s strains to protect from oral pathogens, such as S. mutans and A. actinomycetemcomitans, and prevent pathogen biofilm formation, thus reducing the risk of developing oral infections.

Bifidobacterium animalis subsp. lactis BL050 (DSM 25566)

GiovanniAdmin — Fri, 08 Sep 2023 10:51:13 +0000

Bifidobacterium animalis subsp. lactis BL050 (DSM 25566), developed by SynBalance.
Gastrointestinal Health • Urogenital health • Metabolic Health• Immune prevention

Bactocillin®

GiovanniAdmin — Thu, 17 Aug 2023 10:36:00 +0000

Bactocillin® is a food supplement containing the probiotic strain Bifidobacterium breve PRL2020, the only bacterial strain available on worldwide market with demonstrated resistance to high concentrations of the antibiotics Amoxicillin and Amoxicillin/Clavulanic acid.
This unique feature allows Bactocillin® to be administered simultaneously with these two antibiotics, with the aim of counteracting the re-emergence of pathogenic bacteria and consequently reducing the incidence of diarrhoea and intestinal disorders during antibiotic treatment, while preventing post-antibiotic relapses. The genome of B. breve PRL2020 has been fully sequenced and its safety for use has been established.

Crispact®

GiovanniAdmin — Sat, 10 Jun 2023 10:37:00 +0000

Crispact® is a food supplement containing Lactobacillus crispatus M247.
Clinical studies demonstrated that Crispact® promotes the clearance of HPV infection, showing that 71% of HPV-positive women could test negative for HPV after just 3 months of treatment with Crispact®. Complementary to this data, it was highlighted that the use of Crispact®, again in HPV-positive women who had also concomitant cervical lesion, increased the normalization of cervical cytology by 50% when compared to untreated women.
L. crispatus M247 colonizes 94% of treated women, as shown by clinical trials, moreover, it can even be taken alongside metronidazole, since it was also found to be insensitive to high concentrations of this antibiotic, which is widely prescribed by gynaecologists.

Lactobacillus salivarius – CRL1328

Staff — Thu, 27 Jun 2019 15:13:42 +0000

Inhibition of Enterococcus faecalis, Enterococcus faecium and Neisseria gonorrhoeae • Vaginal health • Prevention of urogenital infections • Inhibition of Candida

Lactobacillus rhamnosus – LR06 (DSM 21981)

Staff — Thu, 27 Jun 2019 15:04:04 +0000

Inhibition of E. coli • Antioxidant activity • Reduced glutathione (GSH) and superoxide dismutase (SOD) production